Announcement on the Use of Own Funds to Purchase Wealth Management Products
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Kanghong Pharmaceutical" or "the Company") and all members of the board guarantee that the content of the information disclosure is true, accurate, and complete, with no false records, misleading statements, or major omissions.
The 18th meeting of the 8th Board of Directors and the 2025 Annual General Meeting approved the proposal on the use of own funds to purchase wealth management products, agreeing that the Company and its subsidiaries may use part of the idle own funds to purchase wealth management products (including structured deposits) within a limit not exceeding RMB 3.8 billion. The purchasing principle is to prioritize high safety, good liquidity, and short-term principal-protected wealth management products issued by commercial banks with a capital protection commitment. The purchasing period is one year from the date of approval by the shareholders' meeting; within the above limit and period, funds can be used on a rolling basis. The board authorized the president and financial officer to exercise specific purchasing decision-making rights based on the above principles, with the finance department responsible for specific purchasing matters. For detailed content, please refer to the Company's designated information disclosure media and the Giant Tide Information Network (www.cninfo.com.cn) published on April 24, 2026, in the "Resolution Announcement of the 18th Meeting of the 8th Board of Directors" (Announcement No. 2026-024), "Announcement on the Use of Own Funds to Purchase Wealth Management Products" (Announcement No. 2026-026), and the "Resolution Announcement of the 2025 Annual General Meeting" (Announcement No. 2026-029).
Recently, the Company has used its own funds to purchase wealth management products. The relevant situation is announced as follows: